Erbitux BLA Resubmission Plan Set; Will Test Accelerated Approval Rules
Bristol and ImClone will take advantage of FDA's new accelerated approval interpretation in resubmitting the BLA for the oncology agent Erbitux
Bristol and ImClone will take advantage of FDA's new accelerated approval interpretation in resubmitting the BLA for the oncology agent Erbitux